Latest News

The team chemically synthesised nearly 300 of the AI-generated genomes and tested them in laboratory conditions, with sixteen of the resulting viruses proving viable.

The companies will combine Evotec’s screening technologies, compound libraries and AI-enabled discovery platform with Odyssey’s expertise in the biology of autoimmune and inflammatory diseases.

The initiative supports Abu Dhabi’s broader strategy to use digital health technologies, real-world evidence and artificial intelligence to advance preventive and personalised healthcare.

Lilly disclosed the decision as part of its second-quarter results, removing a phase 1/2 study of LY3884961 in Gaucher disease type 1 (GD1) from its pipeline.

The technology is designed to improve surgical precision, shorten operating times, reduce blood loss, and accelerate recovery for patients with severe scoliosis and other spinal deformities.

The new venture will initially manufacture biologic drug substances that the two companies mutually select for global markets.

AsymBio plans to use the additional capital to expand its research and development capabilities, GMP manufacturing lines and high-containment facilities.

Through its collaboration with Al Borg Diagnostics, members can schedule laboratory tests at home, reducing the need to visit healthcare facilities while encouraging earlier diagnosis and routine health monitoring.

The hospital successfully conducted two total hip replacement procedures in a carefully planned three-hour operation led by a multidisciplinary team of specialists.

Under the collaboration, Chugai scientists will use Biomni Lab to bring together AI capabilities and diverse biomedical resources within the company’s research environment.